Загрузка...
RB-02 PHASE I/II CLINICAL TRIAL USING TRANS SODIUM CROCETINATE AS A RADIOSENSITIZER FOR GLIOBLASTOMA
BACKGROUND: Trans sodium crocetinate (TSC) was developed at UVA to increase tissue oxygenation. Since hypoxic tumors are more resistant to radiation therapy (RT), TSC was demonstrated to increase survival in a rat GBM model.TSC has been used in an open GBM clinical trial in conjunction with TMZ and...
Сохранить в:
| Опубликовано в: : | Neuro Oncol |
|---|---|
| Главные авторы: | , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Oxford University Press
2014
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4218554/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nou271.2 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|